X4 Pharmaceuticals Inc(XFOR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:42 PM ET (Korea 10/30 05:42)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.19 | Insider Own | 24.29% | Shs Outstand | 96.1M | Perf Week | 4.53% |
| Market Cap | 0.33B | Forward P/E | - | EPS next Y | -7.98% | Insider Trans | -0.43% | Shs Float | 75.1M | Perf Month | 15.34% |
| Enterprise Value | 0.20B | PEG | - | EPS next Q | -0.18 | Inst Own | 79.53% | Short Float | 9.98% | Perf Quarter | -15.95% |
| Income | -0.09B | P/S | 20.92 | EPS this Y | 65.13% | Inst Trans | 3.23% | Short Ratio | 8.83 | Perf Half Y | -17.81% |
| Sales | 0.02B | P/B | 2.07 | EPS next 5Y | 23.57% | ROA | -50.32% | Short Interest | 7.49M | Perf YTD | -16.37% |
| Book/sh | 1.62 | P/C | 1.59 | EPS past 3/5Y | 65.48% 54.19% | ROE | -113.08% | 52W High | -30.75% ($4.83) | Perf Year | -10.56% |
| Cash/sh | 2.1 | P/FCF | - | Sales past 3/5Y | - 63.56% | ROIC | -38.82% | 52W Low | 37.65% ($2.43) | Perf 3Y | -84.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 91.93% | Gross Margin | 80.77% | Volatility(W/M) | 7.74% 6.8% | Perf 5Y | -97.7% |
| Dividend TTM | - | EV/Sales | 12.64 | Sales Y/Y TTM | -51.65% | Oper. Margin | -554.71% | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.02 | EPS Q/Q | 96.32% | Profit Margin | -568.8% | RSI (14) | 60.31 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.3 | Sales Q/Q | 346.33% | SMA20 | 14.31% ($2.93) | Beta | 0.51 | Target Price | $11.6 |
| Payout | - | Debt/Eq | 0.5 | Earnings | 2026/8/6 | SMA50 | 0.15% ($3.34) | Rel Volume | 1.07 | Prev Close | $3.35 |
| Employees | 45 | LT Debt/Eq | 0.49 | EPS/Sales Surpr. | 26.14% 263.88% | SMA200 | -12.04% ($3.81) | Avg Volume(3M) | 0.85M | Price | $3.35 |
| IPO | 2017/11/16 | Option/Short | Yes/Yes | Trades | 4984 | Volume | 906,876 | Change | -0.15% |
A US biotech company developing treatments for rare immune and hematologic diseases. It has an oral chemokine receptor antagonist, mavorixafor (brand name Xolremdi), which received approval for the treatment of WHIM syndrome, and the company is working to expand its indications to other rare diseases such as chronic neutropenia.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded about as much as usual. That is 107% of its average volume.
XFOR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +65.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,092. Peers typically go for $1,237.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 79.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #257 of 594 in the industry
Based on market cap of $332M.
ALEC#256 Alector Inc $332M PER - XFOR#257 X4 Pharmaceuticals Inc $332M PER - 
SCTX#258 Scribe Therapeutics Inc $330M PER - 
TTRX#259 Turn Therapeutics Inc $327M PER - 
PRLD#260 Prelude Therapeutics Inc $327M PER - 
FAQ
What kind of company is XFOR?
XFOR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XFOR?
The market cap of XFOR is approximately $332M, ranking 3,541 within its sector.
What is the 52-week high and low for XFOR?
XFOR has recorded a 52-week high of $4.83 and a low of $2.43.
